Journal
CELLS
Volume 12, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/cells12111523
Keywords
amyotrophic lateral sclerosis; ALS; motor neuron disease; MND; medication; therapy; supportive therapy; clinical trials; personalized medicine
Categories
Ask authors/readers for more resources
Finding effective therapy for ALS is challenging, as the exact cause and pathological pathway are unknown. Current approved drugs only have moderate effects and no curative options are available. Recent breakthroughs in genetic research bring hope for improved treatment, but more efforts are needed.
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder affecting upper and lower motor neurons, with death resulting mainly from respiratory failure three to five years after symptom onset. As the exact underlying causative pathological pathway is unclear and potentially diverse, finding a suitable therapy to slow down or possibly stop disease progression remains challenging. Varying by country Riluzole, Edaravone, and Sodium phenylbutyrate/Taurursodiol are the only drugs currently approved in ALS treatment for their moderate effect on disease progression. Even though curative treatment options, able to prevent or stop disease progression, are still unknown, recent breakthroughs, especially in the field of targeting genetic disease forms, raise hope for improved care and therapy for ALS patients. In this review, we aim to summarize the current state of ALS therapy, including medication as well as supportive therapy, and discuss the ongoing developments and prospects in the field. Furthermore, we highlight the rationale behind the intense research on biomarkers and genetic testing as a feasible way to improve the classification of ALS patients towards personalized medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available